See Our Latest Insights
on the impacts of COVID-19.

$268 Million

ADC Therapeutics

Initial Public Offering

Bookrunner, May 2020

ADC Therapeutics SA is a late clinical-stage biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients suffering from hematological malignancies and solid tumors. The Company’s hematology franchise comprises three clinical-stage product candidates, loncastuximab tesirine (“Lonca” and previously known as ADCT-402), camidanlumab tesirine (“Cami” and previously known as ADCT-301) and ADCT-602. The Company’s solid tumor franchise comprises two clinical-stage product candidates, Cami and ADCT-601, and two pre-clinical product candidates, ADCT-901 and ADCT-701.

More Like This

Feb 2020
$248 Million
Passage Bio logo

Initial Public Offering

Bookrunner

View Details
Feb 2020
$274 Million
Revolution Medicines logo

Initial Public Offering

Bookrunner

View Details
Jan 2020
$183 Million

Initial Public Offering

Bookrunner

View Details